Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dronabinol MDI · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Dronabinol MDI | DRUG | - |
Inclusion Criteria: * Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria Exclusion Criteria: * Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous in...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
Dronabinol MDI is an investigational small molecule being developed for the acute treatment of migraine headache, including migraine with aura and migraine without aura. It is a metered dose inhaler formulation of dronabinol. The drug is currently in Phase 2 clinical development and has not been approved by the FDA.
Dronabinol MDI is being developed by Nektar Therapeutics, a biopharmaceutical company traded on the NASDAQ under the ticker symbol NKTR. The company is conducting clinical trials to evaluate the drug's efficacy and safety for the acute treatment of migraine headache.
Dronabinol MDI is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial has been completed, and the drug is not currently in any active clinical trials.
Dronabinol MDI has one completed Phase 2 clinical trial registered as NCT00123201, titled 'Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache.' The trial was conducted in the United States and enrolled adults aged 18 years and older.
Dronabinol MDI is a metered dose inhaler formulation of dronabinol, the active pharmaceutical ingredient. While dronabinol itself is a known synthetic cannabinoid, Dronabinol MDI refers specifically to this inhaled formulation being developed by Nektar Therapeutics for acute migraine treatment.